Global Hypereosinophilic Syndrome Drug Market

Hypereosinophilic Syndrome Drug Comprehensive Study by Type (Benralizumab, Dasatinib, Dexpramipexole Dihydrochloride, Mepolizumab, Others), Application (Research Center, Hospital, Clinic) Players and Region - Global Market Outlook to 2030

Hypereosinophilic Syndrome Drug Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Hypereosinophilic Syndrome Drug
The hypereosinophilic syndrome drug market is expected to grow due to increased knowledge of the disease, increased investments by major players globally, increased government initiatives, and a robust product pipeline. Hypereosinophilic syndrome (HES) is characterized by a high eosinophil count in the blood. Eosinophils are a type of white blood cell that plays a critical role in the immune system.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Hypereosinophilic Syndrome Drug market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

GlaxoSmithKline plc (United Kingdom), Bristol-Myers Squibb Company (United States), Kyowa Hakko Kirin Co., Ltd. (Japan), Knopp Biosciences LLC (United States), Stemline Therapeutics, Inc. (United States), F. Hoffmann-La Roche AG (Switzerland), Novartis International AG (Switzerland), Teva Pharmaceutical Industries Ltd (Israel), Pfizer Inc (United States) and AstraZeneca plc (United Kingdom) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Hypereosinophilic Syndrome Drug market by Type (Benralizumab, Dasatinib, Dexpramipexole Dihydrochloride, Mepolizumab and Others), Application (Research Center, Hospital and Clinic) and Region.



On the basis of geography, the market of Hypereosinophilic Syndrome Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Influencing Trend:
Surging Recommendation of the Drug from the Doctor

Market Growth Drivers:
Increased Prevalence of Hypereosinophilic Syndrome and Rising Number of Diagnostic Centres

Challenges:
Stringent Government Rules and Regulations

Restraints:
Lack of Knowledge about Hypereosinophilic Syndrome

Opportunities:
Increased Research and Development Investments and Growth in Developing Countries

In September 2020, GlaxoSmithKline plc (GSK) announced the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for the treatment of adult and paediatric patients aged 12 years and older with Hypereosinophilic Syndrome (HES) for ≥ six months without an identifiable non-haematologic secondary cause. The approval makes Nucala the first and only targeted biologic treatment to be approved for patients with this eosinophil-driven disease in the US.


Key Target Audience
Hypereosinophilic Syndrome Drug Manufacturers, Research Organizations and Consulting Companies, New Entrants/Investors, Analysts and Strategic Business Planners, Regulatory & Government Bodies, Downstream Vendors, End Users and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Benralizumab
  • Dasatinib
  • Dexpramipexole Dihydrochloride
  • Mepolizumab
  • Others
By Application
  • Research Center
  • Hospital
  • Clinic
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Hypereosinophilic Syndrome
      • 3.2.2. Rising Number of Diagnostic Centres
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Surging Recommendation of the Drug from the Doctor
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hypereosinophilic Syndrome Drug, by Type, Application and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Hypereosinophilic Syndrome Drug (Value)
      • 5.2.1. Global Hypereosinophilic Syndrome Drug by: Type (Value)
        • 5.2.1.1. Benralizumab
        • 5.2.1.2. Dasatinib
        • 5.2.1.3. Dexpramipexole Dihydrochloride
        • 5.2.1.4. Mepolizumab
        • 5.2.1.5. Others
      • 5.2.2. Global Hypereosinophilic Syndrome Drug by: Application (Value)
        • 5.2.2.1. Research Center
        • 5.2.2.2. Hospital
        • 5.2.2.3. Clinic
      • 5.2.3. Global Hypereosinophilic Syndrome Drug Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Hypereosinophilic Syndrome Drug (Price)
      • 5.3.1. Global Hypereosinophilic Syndrome Drug by: Type (Price)
  • 6. Hypereosinophilic Syndrome Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline plc (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bristol-Myers Squibb Company (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Kyowa Hakko Kirin Co., Ltd. (Japan)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Knopp Biosciences LLC (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Stemline Therapeutics, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. F. Hoffmann-La Roche AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novartis International AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Teva Pharmaceutical Industries Ltd (Israel)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Pfizer Inc (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. AstraZeneca plc (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Hypereosinophilic Syndrome Drug Sale, by Type, Application and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Hypereosinophilic Syndrome Drug (Value)
      • 7.2.1. Global Hypereosinophilic Syndrome Drug by: Type (Value)
        • 7.2.1.1. Benralizumab
        • 7.2.1.2. Dasatinib
        • 7.2.1.3. Dexpramipexole Dihydrochloride
        • 7.2.1.4. Mepolizumab
        • 7.2.1.5. Others
      • 7.2.2. Global Hypereosinophilic Syndrome Drug by: Application (Value)
        • 7.2.2.1. Research Center
        • 7.2.2.2. Hospital
        • 7.2.2.3. Clinic
      • 7.2.3. Global Hypereosinophilic Syndrome Drug Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Hypereosinophilic Syndrome Drug (Price)
      • 7.3.1. Global Hypereosinophilic Syndrome Drug by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hypereosinophilic Syndrome Drug: by Type(USD Million)
  • Table 2. Hypereosinophilic Syndrome Drug Benralizumab , by Region USD Million (2018-2023)
  • Table 3. Hypereosinophilic Syndrome Drug Dasatinib , by Region USD Million (2018-2023)
  • Table 4. Hypereosinophilic Syndrome Drug Dexpramipexole Dihydrochloride , by Region USD Million (2018-2023)
  • Table 5. Hypereosinophilic Syndrome Drug Mepolizumab , by Region USD Million (2018-2023)
  • Table 6. Hypereosinophilic Syndrome Drug Others , by Region USD Million (2018-2023)
  • Table 7. Hypereosinophilic Syndrome Drug: by Application(USD Million)
  • Table 8. Hypereosinophilic Syndrome Drug Research Center , by Region USD Million (2018-2023)
  • Table 9. Hypereosinophilic Syndrome Drug Hospital , by Region USD Million (2018-2023)
  • Table 10. Hypereosinophilic Syndrome Drug Clinic , by Region USD Million (2018-2023)
  • Table 11. South America Hypereosinophilic Syndrome Drug, by Country USD Million (2018-2023)
  • Table 12. South America Hypereosinophilic Syndrome Drug, by Type USD Million (2018-2023)
  • Table 13. South America Hypereosinophilic Syndrome Drug, by Application USD Million (2018-2023)
  • Table 14. Brazil Hypereosinophilic Syndrome Drug, by Type USD Million (2018-2023)
  • Table 15. Brazil Hypereosinophilic Syndrome Drug, by Application USD Million (2018-2023)
  • Table 16. Argentina Hypereosinophilic Syndrome Drug, by Type USD Million (2018-2023)
  • Table 17. Argentina Hypereosinophilic Syndrome Drug, by Application USD Million (2018-2023)
  • Table 18. Rest of South America Hypereosinophilic Syndrome Drug, by Type USD Million (2018-2023)
  • Table 19. Rest of South America Hypereosinophilic Syndrome Drug, by Application USD Million (2018-2023)
  • Table 20. Asia Pacific Hypereosinophilic Syndrome Drug, by Country USD Million (2018-2023)
  • Table 21. Asia Pacific Hypereosinophilic Syndrome Drug, by Type USD Million (2018-2023)
  • Table 22. Asia Pacific Hypereosinophilic Syndrome Drug, by Application USD Million (2018-2023)
  • Table 23. China Hypereosinophilic Syndrome Drug, by Type USD Million (2018-2023)
  • Table 24. China Hypereosinophilic Syndrome Drug, by Application USD Million (2018-2023)
  • Table 25. Japan Hypereosinophilic Syndrome Drug, by Type USD Million (2018-2023)
  • Table 26. Japan Hypereosinophilic Syndrome Drug, by Application USD Million (2018-2023)
  • Table 27. India Hypereosinophilic Syndrome Drug, by Type USD Million (2018-2023)
  • Table 28. India Hypereosinophilic Syndrome Drug, by Application USD Million (2018-2023)
  • Table 29. South Korea Hypereosinophilic Syndrome Drug, by Type USD Million (2018-2023)
  • Table 30. South Korea Hypereosinophilic Syndrome Drug, by Application USD Million (2018-2023)
  • Table 31. Taiwan Hypereosinophilic Syndrome Drug, by Type USD Million (2018-2023)
  • Table 32. Taiwan Hypereosinophilic Syndrome Drug, by Application USD Million (2018-2023)
  • Table 33. Australia Hypereosinophilic Syndrome Drug, by Type USD Million (2018-2023)
  • Table 34. Australia Hypereosinophilic Syndrome Drug, by Application USD Million (2018-2023)
  • Table 35. Rest of Asia-Pacific Hypereosinophilic Syndrome Drug, by Type USD Million (2018-2023)
  • Table 36. Rest of Asia-Pacific Hypereosinophilic Syndrome Drug, by Application USD Million (2018-2023)
  • Table 37. Europe Hypereosinophilic Syndrome Drug, by Country USD Million (2018-2023)
  • Table 38. Europe Hypereosinophilic Syndrome Drug, by Type USD Million (2018-2023)
  • Table 39. Europe Hypereosinophilic Syndrome Drug, by Application USD Million (2018-2023)
  • Table 40. Germany Hypereosinophilic Syndrome Drug, by Type USD Million (2018-2023)
  • Table 41. Germany Hypereosinophilic Syndrome Drug, by Application USD Million (2018-2023)
  • Table 42. France Hypereosinophilic Syndrome Drug, by Type USD Million (2018-2023)
  • Table 43. France Hypereosinophilic Syndrome Drug, by Application USD Million (2018-2023)
  • Table 44. Italy Hypereosinophilic Syndrome Drug, by Type USD Million (2018-2023)
  • Table 45. Italy Hypereosinophilic Syndrome Drug, by Application USD Million (2018-2023)
  • Table 46. United Kingdom Hypereosinophilic Syndrome Drug, by Type USD Million (2018-2023)
  • Table 47. United Kingdom Hypereosinophilic Syndrome Drug, by Application USD Million (2018-2023)
  • Table 48. Netherlands Hypereosinophilic Syndrome Drug, by Type USD Million (2018-2023)
  • Table 49. Netherlands Hypereosinophilic Syndrome Drug, by Application USD Million (2018-2023)
  • Table 50. Rest of Europe Hypereosinophilic Syndrome Drug, by Type USD Million (2018-2023)
  • Table 51. Rest of Europe Hypereosinophilic Syndrome Drug, by Application USD Million (2018-2023)
  • Table 52. MEA Hypereosinophilic Syndrome Drug, by Country USD Million (2018-2023)
  • Table 53. MEA Hypereosinophilic Syndrome Drug, by Type USD Million (2018-2023)
  • Table 54. MEA Hypereosinophilic Syndrome Drug, by Application USD Million (2018-2023)
  • Table 55. Middle East Hypereosinophilic Syndrome Drug, by Type USD Million (2018-2023)
  • Table 56. Middle East Hypereosinophilic Syndrome Drug, by Application USD Million (2018-2023)
  • Table 57. Africa Hypereosinophilic Syndrome Drug, by Type USD Million (2018-2023)
  • Table 58. Africa Hypereosinophilic Syndrome Drug, by Application USD Million (2018-2023)
  • Table 59. North America Hypereosinophilic Syndrome Drug, by Country USD Million (2018-2023)
  • Table 60. North America Hypereosinophilic Syndrome Drug, by Type USD Million (2018-2023)
  • Table 61. North America Hypereosinophilic Syndrome Drug, by Application USD Million (2018-2023)
  • Table 62. United States Hypereosinophilic Syndrome Drug, by Type USD Million (2018-2023)
  • Table 63. United States Hypereosinophilic Syndrome Drug, by Application USD Million (2018-2023)
  • Table 64. Canada Hypereosinophilic Syndrome Drug, by Type USD Million (2018-2023)
  • Table 65. Canada Hypereosinophilic Syndrome Drug, by Application USD Million (2018-2023)
  • Table 66. Mexico Hypereosinophilic Syndrome Drug, by Type USD Million (2018-2023)
  • Table 67. Mexico Hypereosinophilic Syndrome Drug, by Application USD Million (2018-2023)
  • Table 68. Hypereosinophilic Syndrome Drug: by Type(USD/Units)
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Hypereosinophilic Syndrome Drug: by Type(USD Million)
  • Table 80. Hypereosinophilic Syndrome Drug Benralizumab , by Region USD Million (2025-2030)
  • Table 81. Hypereosinophilic Syndrome Drug Dasatinib , by Region USD Million (2025-2030)
  • Table 82. Hypereosinophilic Syndrome Drug Dexpramipexole Dihydrochloride , by Region USD Million (2025-2030)
  • Table 83. Hypereosinophilic Syndrome Drug Mepolizumab , by Region USD Million (2025-2030)
  • Table 84. Hypereosinophilic Syndrome Drug Others , by Region USD Million (2025-2030)
  • Table 85. Hypereosinophilic Syndrome Drug: by Application(USD Million)
  • Table 86. Hypereosinophilic Syndrome Drug Research Center , by Region USD Million (2025-2030)
  • Table 87. Hypereosinophilic Syndrome Drug Hospital , by Region USD Million (2025-2030)
  • Table 88. Hypereosinophilic Syndrome Drug Clinic , by Region USD Million (2025-2030)
  • Table 89. South America Hypereosinophilic Syndrome Drug, by Country USD Million (2025-2030)
  • Table 90. South America Hypereosinophilic Syndrome Drug, by Type USD Million (2025-2030)
  • Table 91. South America Hypereosinophilic Syndrome Drug, by Application USD Million (2025-2030)
  • Table 92. Brazil Hypereosinophilic Syndrome Drug, by Type USD Million (2025-2030)
  • Table 93. Brazil Hypereosinophilic Syndrome Drug, by Application USD Million (2025-2030)
  • Table 94. Argentina Hypereosinophilic Syndrome Drug, by Type USD Million (2025-2030)
  • Table 95. Argentina Hypereosinophilic Syndrome Drug, by Application USD Million (2025-2030)
  • Table 96. Rest of South America Hypereosinophilic Syndrome Drug, by Type USD Million (2025-2030)
  • Table 97. Rest of South America Hypereosinophilic Syndrome Drug, by Application USD Million (2025-2030)
  • Table 98. Asia Pacific Hypereosinophilic Syndrome Drug, by Country USD Million (2025-2030)
  • Table 99. Asia Pacific Hypereosinophilic Syndrome Drug, by Type USD Million (2025-2030)
  • Table 100. Asia Pacific Hypereosinophilic Syndrome Drug, by Application USD Million (2025-2030)
  • Table 101. China Hypereosinophilic Syndrome Drug, by Type USD Million (2025-2030)
  • Table 102. China Hypereosinophilic Syndrome Drug, by Application USD Million (2025-2030)
  • Table 103. Japan Hypereosinophilic Syndrome Drug, by Type USD Million (2025-2030)
  • Table 104. Japan Hypereosinophilic Syndrome Drug, by Application USD Million (2025-2030)
  • Table 105. India Hypereosinophilic Syndrome Drug, by Type USD Million (2025-2030)
  • Table 106. India Hypereosinophilic Syndrome Drug, by Application USD Million (2025-2030)
  • Table 107. South Korea Hypereosinophilic Syndrome Drug, by Type USD Million (2025-2030)
  • Table 108. South Korea Hypereosinophilic Syndrome Drug, by Application USD Million (2025-2030)
  • Table 109. Taiwan Hypereosinophilic Syndrome Drug, by Type USD Million (2025-2030)
  • Table 110. Taiwan Hypereosinophilic Syndrome Drug, by Application USD Million (2025-2030)
  • Table 111. Australia Hypereosinophilic Syndrome Drug, by Type USD Million (2025-2030)
  • Table 112. Australia Hypereosinophilic Syndrome Drug, by Application USD Million (2025-2030)
  • Table 113. Rest of Asia-Pacific Hypereosinophilic Syndrome Drug, by Type USD Million (2025-2030)
  • Table 114. Rest of Asia-Pacific Hypereosinophilic Syndrome Drug, by Application USD Million (2025-2030)
  • Table 115. Europe Hypereosinophilic Syndrome Drug, by Country USD Million (2025-2030)
  • Table 116. Europe Hypereosinophilic Syndrome Drug, by Type USD Million (2025-2030)
  • Table 117. Europe Hypereosinophilic Syndrome Drug, by Application USD Million (2025-2030)
  • Table 118. Germany Hypereosinophilic Syndrome Drug, by Type USD Million (2025-2030)
  • Table 119. Germany Hypereosinophilic Syndrome Drug, by Application USD Million (2025-2030)
  • Table 120. France Hypereosinophilic Syndrome Drug, by Type USD Million (2025-2030)
  • Table 121. France Hypereosinophilic Syndrome Drug, by Application USD Million (2025-2030)
  • Table 122. Italy Hypereosinophilic Syndrome Drug, by Type USD Million (2025-2030)
  • Table 123. Italy Hypereosinophilic Syndrome Drug, by Application USD Million (2025-2030)
  • Table 124. United Kingdom Hypereosinophilic Syndrome Drug, by Type USD Million (2025-2030)
  • Table 125. United Kingdom Hypereosinophilic Syndrome Drug, by Application USD Million (2025-2030)
  • Table 126. Netherlands Hypereosinophilic Syndrome Drug, by Type USD Million (2025-2030)
  • Table 127. Netherlands Hypereosinophilic Syndrome Drug, by Application USD Million (2025-2030)
  • Table 128. Rest of Europe Hypereosinophilic Syndrome Drug, by Type USD Million (2025-2030)
  • Table 129. Rest of Europe Hypereosinophilic Syndrome Drug, by Application USD Million (2025-2030)
  • Table 130. MEA Hypereosinophilic Syndrome Drug, by Country USD Million (2025-2030)
  • Table 131. MEA Hypereosinophilic Syndrome Drug, by Type USD Million (2025-2030)
  • Table 132. MEA Hypereosinophilic Syndrome Drug, by Application USD Million (2025-2030)
  • Table 133. Middle East Hypereosinophilic Syndrome Drug, by Type USD Million (2025-2030)
  • Table 134. Middle East Hypereosinophilic Syndrome Drug, by Application USD Million (2025-2030)
  • Table 135. Africa Hypereosinophilic Syndrome Drug, by Type USD Million (2025-2030)
  • Table 136. Africa Hypereosinophilic Syndrome Drug, by Application USD Million (2025-2030)
  • Table 137. North America Hypereosinophilic Syndrome Drug, by Country USD Million (2025-2030)
  • Table 138. North America Hypereosinophilic Syndrome Drug, by Type USD Million (2025-2030)
  • Table 139. North America Hypereosinophilic Syndrome Drug, by Application USD Million (2025-2030)
  • Table 140. United States Hypereosinophilic Syndrome Drug, by Type USD Million (2025-2030)
  • Table 141. United States Hypereosinophilic Syndrome Drug, by Application USD Million (2025-2030)
  • Table 142. Canada Hypereosinophilic Syndrome Drug, by Type USD Million (2025-2030)
  • Table 143. Canada Hypereosinophilic Syndrome Drug, by Application USD Million (2025-2030)
  • Table 144. Mexico Hypereosinophilic Syndrome Drug, by Type USD Million (2025-2030)
  • Table 145. Mexico Hypereosinophilic Syndrome Drug, by Application USD Million (2025-2030)
  • Table 146. Hypereosinophilic Syndrome Drug: by Type(USD/Units)
  • Table 147. Research Programs/Design for This Report
  • Table 148. Key Data Information from Secondary Sources
  • Table 149. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hypereosinophilic Syndrome Drug: by Type USD Million (2018-2023)
  • Figure 5. Global Hypereosinophilic Syndrome Drug: by Application USD Million (2018-2023)
  • Figure 6. South America Hypereosinophilic Syndrome Drug Share (%), by Country
  • Figure 7. Asia Pacific Hypereosinophilic Syndrome Drug Share (%), by Country
  • Figure 8. Europe Hypereosinophilic Syndrome Drug Share (%), by Country
  • Figure 9. MEA Hypereosinophilic Syndrome Drug Share (%), by Country
  • Figure 10. North America Hypereosinophilic Syndrome Drug Share (%), by Country
  • Figure 11. Global Hypereosinophilic Syndrome Drug: by Type USD/Units (2018-2023)
  • Figure 12. Global Hypereosinophilic Syndrome Drug share by Players 2023 (%)
  • Figure 13. Global Hypereosinophilic Syndrome Drug share by Players (Top 3) 2023(%)
  • Figure 14. Global Hypereosinophilic Syndrome Drug share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 17. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2023
  • Figure 18. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 19. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2023
  • Figure 20. Kyowa Hakko Kirin Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 21. Kyowa Hakko Kirin Co., Ltd. (Japan) Revenue: by Geography 2023
  • Figure 22. Knopp Biosciences LLC (United States) Revenue, Net Income and Gross profit
  • Figure 23. Knopp Biosciences LLC (United States) Revenue: by Geography 2023
  • Figure 24. Stemline Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Stemline Therapeutics, Inc. (United States) Revenue: by Geography 2023
  • Figure 26. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 27. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2023
  • Figure 28. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 29. Novartis International AG (Switzerland) Revenue: by Geography 2023
  • Figure 30. Teva Pharmaceutical Industries Ltd (Israel) Revenue, Net Income and Gross profit
  • Figure 31. Teva Pharmaceutical Industries Ltd (Israel) Revenue: by Geography 2023
  • Figure 32. Pfizer Inc (United States) Revenue, Net Income and Gross profit
  • Figure 33. Pfizer Inc (United States) Revenue: by Geography 2023
  • Figure 34. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 35. AstraZeneca plc (United Kingdom) Revenue: by Geography 2023
  • Figure 36. Global Hypereosinophilic Syndrome Drug: by Type USD Million (2025-2030)
  • Figure 37. Global Hypereosinophilic Syndrome Drug: by Application USD Million (2025-2030)
  • Figure 38. South America Hypereosinophilic Syndrome Drug Share (%), by Country
  • Figure 39. Asia Pacific Hypereosinophilic Syndrome Drug Share (%), by Country
  • Figure 40. Europe Hypereosinophilic Syndrome Drug Share (%), by Country
  • Figure 41. MEA Hypereosinophilic Syndrome Drug Share (%), by Country
  • Figure 42. North America Hypereosinophilic Syndrome Drug Share (%), by Country
  • Figure 43. Global Hypereosinophilic Syndrome Drug: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline plc (United Kingdom)
  • Bristol-Myers Squibb Company (United States)
  • Kyowa Hakko Kirin Co., Ltd. (Japan)
  • Knopp Biosciences LLC (United States)
  • Stemline Therapeutics, Inc. (United States)
  • F. Hoffmann-La Roche AG (Switzerland)
  • Novartis International AG (Switzerland)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Pfizer Inc (United States)
  • AstraZeneca plc (United Kingdom)
Select User Access Type

Key Highlights of Report


Mar 2024 246 Pages 58 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Hypereosinophilic Syndrome Drug Market Quantitative research analysis
Global Hypereosinophilic Syndrome Drug Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as GlaxoSmithKline plc (United Kingdom), Bristol-Myers Squibb Company (United States), Kyowa Hakko Kirin Co., Ltd. (Japan), Knopp Biosciences LLC (United States), Stemline Therapeutics, Inc. (United States), F. Hoffmann-La Roche AG (Switzerland), Novartis International AG (Switzerland), Teva Pharmaceutical Industries Ltd (Israel), Pfizer Inc (United States) and AstraZeneca plc (United Kingdom) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Surging Recommendation of the Drug from the Doctor" is seen as one of major influencing trends for Hypereosinophilic Syndrome Drug Market during projected period 2023-2030.
The Hypereosinophilic Syndrome Drug market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Hypereosinophilic Syndrome Drug Market Report?

Have a Query? Click Here

Other Related Reports

Pulmonary Hypertension Drug Comprehensive Study by Type (IK-3001, Sildenafil Citrate IMD, IK-7002, Riociguat, SAR-407899, Others), Application (Early-Stage Drug Candidates (Phase I & Phase II), Late-...
$ 3450
Pharmaceutical Filtration Comprehensive Study by Type (Membrane Filters {MCE Membrane Filters, Coated Cellulose Acetate Membrane Filters, Nylon Membrane Filters, PTFE Membrane Filters, PVDF Membrane...
$ 3750
Hemophilia Drugs Comprehensive Study by Type (Hemlibra, Benefix, Advate, Novoseven RT, Eloctate, Humate-P, Others), Application (Recombinant Therapies, Plasma-Derived Therapies), Distribution Channel...
$ 3750
Methotrexate Comprehensive Study by Type (Tablet, Injection), Application (Cancer, Arthritis, Auto-Immune Diseases, Others), Sales Channel (Pharmacy Stores, Online Pharmacies), Dosage (5 mg, 7.5 mg, ...
$ 3450
Effervescent Products Comprehensive Study by Type (Prescription-Based, Daily-Use), Application (Pharmaceuticals, Functional Foods (Probiotics, Dietary Supplements, Electrolytes & Energy Boosting Supp...
$ 3750
Ibrutinib Comprehensive Study by Application (Chronic Lymphocytic Leukaemia (CLL), Mantle Cell Lymphoma (MCL), Diffuse Large B Cell Lymphoma (DLBCL), Multiple Myeloma (MM), Follicular Lymphoma (FL), ...
$ 3650